Diurnal (#DNL) – recommended 27.5p per share acquisition
- 2022-08-30 07:59:58
A “Directorate Change and Management Updates” announcement from Diurnal Group (DNL) includes that David Bevan, with over 30 years of broad base expertise in the industry, has been promoted to a newly created role of Chief Business Officer. Though, with shares in the group currently down more than 4.5% to 15.25p, what else does the announcement include?...
Hormonal diseases-targeting pharmaceutical group Diurnal (DNL) has announced results for its half-year ended 31st December 2021 including “Alkindi product sales (including royalties) for the period increased to £1.74m, representing year-on-year growth of 46%… Efmody initial product sales for the period of £0.39m were in line with the company's expectations”. So why a share price response to below 18p, more than 46% lower?!...







